BioCentury | Jan 29, 2020
Product Development

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

Under the leadership of incoming CEO Laurence Reid, hearing loss company Decibel is starting its next chapter in drug discovery with a narrowed focus on inner ear cell regeneration and programs in balance disorders. Reid...
BC Innovations | Apr 5, 2019
Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
BC Innovations | Nov 16, 2017
Emerging Company Profile

YAP off, YAP on

Vivace Therapeutics Inc. exploits opposite angles of the Hippo-YAP pathway, with first-in-class inhibitors that turn it off in cancers with activating mutations and activators that turn it on to enhance tumor immunogenicity in other cancers....
BC Innovations | Sep 14, 2017
Targets & Mechanisms

Platelets YAP at cancer

While elevated platelet levels often signify an underlying malignancy, the molecular mechanisms linking the two are not well understood. Now, a team from MD Anderson has shown a well-known, but barely exploited signaling pathway mediates...
BC Innovations | Aug 3, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jul 5, 2017
Finance

Cross-border cachet

Vivace Therapeutics Inc. ’s investors are hoping to leverage the management team’s experience running a U.S.-China cancer company, but this time the goal is to retain more value by advancing the programs into the clinic....
BC Week In Review | Jul 5, 2017
Financial News

Vivace emerges from stealth with $25M series B round

Vivace Therapeutics Inc. (San Mateo, Calif.) emerged from stealth mode on June 28, saying it raised $25 million in a series B round led by new investor Cenova Capital. Also participating were new investor Sequoia...
BC Extra | Jun 28, 2017
Financial News

Vivace out of stealth with $40M in two rounds

Cancer play Vivace Therapeutics Inc. (San Mateo, Calif.) emerged from stealth mode and announced a $25 million series B round led by new investor Cenova Capital. Also participating were new investor Sequoia Capital China and...
BC Innovations | Mar 18, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lung cancer MicroRNA-31 (miR-31); LATS large tumor suppressor homolog 2 (LATS2); protein phosphatase 2 regulatory subunit B a-isoform (PPP2R2A); protein phosphatase 2 (PPP2CA; PP2A) Studies...
Items per page:
1 - 9 of 9